Keywords: Germany, IQWiG, AMNOG, Bristol-Myers, Yervoy, GlaxoSmithKline, Benlysta, Biogen Idec, Fampyra, Melanoma, Lupus, Multiple sclerosis

Germany's IQWiG finds in favor of Yervoy but not Benlysta or Fampyra

Article | 09 May 2012

Print This

The German Institute for Quality and Efficiency in Health Care (IQWiG) in the past few days issued a mixed batch ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in